Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Immune Therapy Suppliers In Europe
5 companies found
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
based inIssoire, FRANCE
An allogeneic platform designed to generate first in class immune therapy with the goal of harnessing the patient immune system and preventing resistance to cancer treatment. Our mission at Brenus is to provide a solution to cold solid tumors – ...
based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal ...